Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00539994 | Retapamulin Ointment in Healthy Adults Nasally Colonized With Staphylococcus Aureus | PHASE2 | COMPLETED | 57 | — | — | Sep 1, 2007 | Jan 1, 2008 | Dec 15, 2016 | 4 | United States |
Area under the plasma concentration curve (AUC) is used to calculate drug clearance and bioavailability using plasma concentration and time curve.
Area under the plasma concentration curve (AUC) is used to calculate drug clearance and bioavailability using plasma concentration and time curve.
Cmax is the peak serum concentration. Low value was not calculable, and High value was 2.74 ng/mL.
Cmax is the peak serum concentration. Low value was not calculable, and high value was 2.74 ng/mL
Subjects who tested positive as persistent carriers of S. Aureus who on day 12 are negative and have been eradicated of S. Aureus.
| Arm | Type | Description |
|---|---|---|
| Treatment B | EXPERIMENTAL | 200mg BID retapamulin 5 days |
| Treatment C | PLACEBO_COMPARATOR | 200mg BID placebo 5 days |
| Treatment A | EXPERIMENTAL | 200mg BID retapamulin 3 days and placebo BID 2 days for a total of 5 days |
| Name | Type | Description |
|---|---|---|
| retapamulin | DRUG | 200mg BID retapamulin 3 days |
| Placebo | DRUG | 200mg BID placebo 5 days |
Inclusion Criteria: * Male and female subjects between the ages of 18 and 65, inclusive. A female is eligible to enter and participate in this study if she is non-pregnant, nonlactating and if she is of: * non-childbearing potential (i.e., physiologically incapable of becoming pregnant), includi...